IMEXHS delivers an advanced, AI-native cloud RIS/PACS platform that reduces operational costs, improves clinical outcomes, and accelerates diagnostic workflows. Through Aquila+, healthcare institutions eliminate CAPEX investment and benefit from the fastest deployment in the market — months to days — with five proprietary AI Agents embedded across the full radiology workflow. The platform maintains 99.8% uptime, SLA compliance above 95.5%, and 24/7 support under ITIL standards, backed by ISO 9001, ISO 13485 and ISO 27001:2022 certifications. With 8.2M+ studies processed annually across 564 installed sites in 18 countries, IMEXHS delivers measurable outcomes at scale. 

IMEXHS operates in a large, resilient and underpenetrated market. Medical imaging technology in Latin America represents a total addressable opportunity of over USD 200M in annual recurring revenue, in an industry projected to grow at a CAGR above 5% over the next decade and structurally resistant to macroeconomic cycles.

The Company has reached a clear financial inflection point. ARR grew to $34.8M, up 16% on the prior year, supported by double-digit revenue growth, positive underlying EBITDA, positive net cash flow and healthy gross margins. Operationally, the platform processes 8.2M+ studies annually across 564 installed sites in 18 countries, maintaining 99.8% uptime and a Net Promoter Score of 58. A network of 27 active partners across 14 countries extends the Company's commercial reach without proportional cost growth.

IMEXHS also holds a structural advantage in its core markets: deep local knowledge, regulatory approvals across key Latin American markets, and a development and support team based in the region — enabling the Company to adapt to local complexity and compete effectively against larger global providers.

IMEXHS generates recurring revenue through two complementary streams: software subscriptions and radiology services. As at 30 June 2025, the Company reported total ARR of $34.8M, comprising Software ARR of $11.8M and Radiology ARR of $23.0M, representing overall growth of 16% on the prior year.

Software ARR is driven by subscription fees from Aquila+, the Company's cloud-native RIS/PACS platform, deployed across 564 installed sites in 18 countries. Radiology ARR is generated through RIMAB, the Company's radiology services division, which provides teleradiology and reporting services to healthcare providers across the region.

Growth is supported by three pathways: geographic expansion into new markets, cross-sell and upsell within the existing client base, and a partner-led distribution model — with 27 active partners across 14 countries contributing $904K in partner-led ARR in FY25. Hard-currency pricing across key markets further strengthens the quality and predictability of the recurring revenue base.